| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | LAMM; MDC1A |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human LAMA2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于LAMA2抗体的3篇参考文献示例(文献信息为虚构，仅用于示例格式)：
---
1. **文献名称**: *Laminin α2 (LAMA2) Antibody Specificity Validation in Muscular Dystrophy Models*
**作者**: Smith J, et al.
**摘要**: 本研究验证了一种新型LAMA2单克隆抗体在先天性肌营养不良小鼠模型中的特异性。通过免疫组织化学和Western blot分析，证实该抗体可精准识别LAMA2蛋白的C端结构域，并用于患者肌肉活检样本的病理诊断。
---
2. **文献名称**: *Development of a High-Affinity Rabbit Polyclonal Antibody Against LAMA2 for Extracellular Matrix Studies*
**作者**: Lee H, et al.
**摘要**: 报道了一种兔源多克隆抗体的开发流程，该抗体靶向LAMA2的G结构域。实验表明其适用于免疫荧光染色和流式细胞术，成功用于分析层黏连蛋白在神经肌肉接头处的分布。
---
3. **文献名称**: *LAMA2 Antibody-Based Biomarker Screening in Congenital Muscular Dystrophy*
**作者**: García R, et al.
**摘要**: 利用LAMA2抗体对100例临床样本进行ELISA检测，发现LAMA2表达水平与疾病严重程度显著相关。研究强调了该抗体在无创诊断和疗效评估中的潜在应用价值。
---
(注：以上文献为示例模板，实际文献需通过PubMed或学术数据库检索获取。)
The LAMA2 antibody targets the laminin alpha-2 chain, a critical component of the extracellular matrix protein laminin-211 (also known as merosin). Encoded by the *LAMA2* gene, this subunit is predominantly expressed in the basement membranes of skeletal muscle, Schwann cells, and the brain. Laminin-211 plays a vital role in tissue integrity, cell adhesion, and signaling, particularly during muscle development and nerve myelination. Mutations in *LAMA2* are linked to congenital muscular dystrophy type 1A (MDC1A), a severe autosomal recessive disorder characterized by muscle weakness, respiratory complications, and delayed motor function.
LAMA2 antibodies are essential tools in research and diagnostics, enabling the detection of laminin alpha-2 deficiency in patient biopsies via immunohistochemistry or Western blot. These antibodies help confirm MDC1A diagnoses and differentiate them from other muscular dystrophies. In preclinical studies, they aid in evaluating therapeutic strategies, such as gene therapy or laminin supplementation, to restore functional protein expression. Commercially available LAMA2 antibodies are typically monoclonal or polyclonal, validated for specificity across human, mouse, and rat models. Ongoing research continues to explore laminin-211's role in neuromuscular pathology and its potential as a biomarker or therapeutic target.
×
